About Infertility Services
Infertility is the failure to achieve pregnancy after 12 months of unprotected intercourse. Infertility occurs due to the abnormal functioning of the female and male reproductive system. It can be treated with infertility drugs and through procedures such as artificial insemination, in-vitro fertilization, and surrogacy.
Technavio’s analysts forecast the infertility services market in US to grow at a CAGR of 4.65% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the infertility services market in US for 2017-2021. To calculate the market size, the report considers the services carried out during treatment via infertility drugs and assisted reproductive technology (ART) services.
Technavio's report, Infertility Services Market in US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• CARE facility
• CooperSurgical
• Ferring Pharmaceuticals
• Monash IVF
• Merck
• Vitrolife
Other prominent vendors
• AbbVie
• Apricus Biosciences
• AstraZeneca
• Auxogyn
• Eli Lilly
• EMD Serono
• IKS International
• InVitro Care
• INVO Bioscience
• Irvine Scientific
• LifeGlobal
• MedITEX
• NMC Health
• OB GYN Associates
• OvaScience
• Pantec Biosolutions
• Reproductive Medicine Associates of New Jersey
• The Sims Clinic
• TriHealth
• Virtus Health
• Xytex Cryo International
Market driver
• Rising success rate of infertility treatments.
• For a full, detailed list, view our report
Market challenge
• Limited reimbursements and lack of strict regulatory oversight.
• For a full, detailed list, view our report
Market trend
• Upsurge in mergers and acquisitions.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Vendor analysis
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Market segmentation by underlying cause
PART 07: Market segmentation by services
• Market overview
• ART services market in US
• Infertility drugs services market in US
PART 08: Market drivers
PART 09: Impact of drivers
PART 10: Market challenges
PART 11: Impact of drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
• Competitive scenario
• Other prominent vendors
PART 14: Key Vendor Analysis
• CARE Fertility
• CooperSurgical
• Ferring Pharmaceuticals
• Monash IVF
• Merck
• Vitrolife
PART 15: Appendix
• List of abbreviations
PART 16: Explore Technavio
List of Exhibits
Exhibit 01: US infertility services market segmentation: Overview
Exhibit 02: Product offerings
Exhibit 03: Assessment of regulatory bodies
Exhibit 04: Snapshot: Infertility services market in US
Exhibit 05: US fertility chart 2015
Exhibit 06: Stages of infertility treatment
Exhibit 07: Infertility services market in the US 2016-2021 ($ billions)
Exhibit 08: Side effects and success rates of infertility services in US
Exhibit 09: Impact of various factors on infertility services in US
Exhibit 10: Recommendations to vendors
Exhibit 11: Five forces analysis
Exhibit 12: Infertility services market in US by underlying cause
Exhibit 13: Diagnosis of infertility
Exhibit 14: Market segmentation by services 2016-2021(in %)
Exhibit 15: Snapshot: US fertility services market by product
Exhibit 16: Categories of ART services 2016
Exhibit 17: IVF overview
Exhibit 18: ART services market in US 2016-2021 ($ billions)
Exhibit 19: Comparison of fresh and frozen ART cycle
Exhibit 20: Infertility drugs services market in US 2016-2021($ billions)
Exhibit 21: Success rate of IVF procedures
Exhibit 22: ART procedures in US (in thousands)
Exhibit 23: Obesity prevalence in the US (2015)
Exhibit 24: Infertility rates by age
Exhibit 25: US birth rates by women
Exhibit 26: Impact of drivers
Exhibit 27: Cost breakdown of IVF by various stages in US
Exhibit 28: Impact of drivers and challenges
Exhibit 29: Notable M&A activity
Exhibit 30: Same sex married couples in US
Exhibit 31: CARE Fertility: Profile
Exhibit 32: CARE Fertility: Strength analysis
Exhibit 33: CARE Fertility: Strategy assessment
Exhibit 34: CARE Fertility: Opportunity assessment
Exhibit 35: CooperSurgical: Profile
Exhibit 36: CooperSurgical: Strength analysis
Exhibit 37: CooperSurgical: Growth strategy assessment
Exhibit 38: CooperSurgical: Opportunity assessment
Exhibit 39: Ferring Pharmaceuticals: Profile
Exhibit 40: Ferring Pharmaceuticals: Strength analysis
Exhibit 41: Ferring Pharmaceuticals: Strategy assessment
Exhibit 42: Ferring Pharmaceuticals: Opportunity assessment
Exhibit 43: Monash IVF: Profile
Exhibit 44: Monash IVF: Strength analysis
Exhibit 45: Monash IVF: Strategy assessment
Exhibit 46: Monash IVF: Opportunity assessment
Exhibit 47: Merck: Profile
Exhibit 48: Merck: Strength analysis
Exhibit 49: Merck: Strategy assessment
Exhibit 50: Merck: Opportunity assessment
Exhibit 51: Vitrolife: Profile
Exhibit 52: Vitrolife: Strength analysis
Exhibit 53: Vitrolife: Strategy assessment
Exhibit 54: Vitrolife: Opportunity assessment
